Beam Therapeutics Inc stock is traded at $25.79, with a volume of 2,732,219. It is down -7.20% in the last 24 hours and up +0.47% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Previous Close:
$27.79
Open:
$27.37
24h Volume:
2,732,219
Relative Volume:
1.37
Market Cap:
$2.67B
Revenue:
$164.01M
Net Income/Loss:
-$65.04M
P/E Ratio:
-
EPS:
-$0.687
Net Cash Flow:
-$383.84M
1W Performance:
-10.58%
1M Performance:
+0.47%
6M Performance:
-10.76%
1Y Performance:
+11.79%
1-Day Range:
$24.88$27.48
1-Week Range:
$24.88$28.85
52-Week Range:
$20.23$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-327-8775Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS